论文部分内容阅读
CD44是由单一基因所编码的具有高度异质性的单链膜表面糖蛋白家族,介导细胞与细胞、细胞与细胞外基质之间的黏附作用,其拼接变异体的不同构成了其基因产物的多样性;尤其拼接变异体V6(CD44v6)被认为具有致瘤性;CD44v6在一定程度上参与了肿瘤的发生发展,是预后因子之一,并且可能作为肿瘤进展的标志物。CD44v6的过表达与肿瘤的侵袭、转移和临床分期有关。对CD44v6的检测不仅能预测患者的预后,而且还可为肿瘤的个体化治疗直接提供信息。
CD44 is a highly heterogeneous family of single-chain membrane glycoproteins encoded by a single gene that mediates cell-cell, cell-cell and extracellular matrix adhesion. The splicing variants of CD44 constitute their gene products In particular, the splicing variant V6 (CD44v6) is considered to be tumorigenic. CD44v6 is involved in tumor development to a certain extent and is one of the prognostic factors and may serve as a marker of tumor progression. Overexpression of CD44v6 is associated with tumor invasion, metastasis and clinical stage. The detection of CD44v6 not only predicts the patient’s prognosis, but also provides information directly for the individualized treatment of tumors.